Clinical trials: Patients With Diabetes.
Type 1 Diabetes
Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting.
- Trial name
- NCT02748018
- Testing
- 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
- Where
- 36 sites in United States, Canada and 7 more
- Volunteers
- 959 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications…
- Trial name
- NCT03338010
- Testing
- LY2963016, Lantus®
- Where
- 32 sites in China
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist…
- Trial name
- NCT00350779
- Testing
- sitagliptin, rosiglitazone, metformin
- Volunteers
- 262 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Dapagliflozin Patient Satisfaction Survey
The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus
- Trial name
- NCT02805283
- Where
- United States
- Volunteers
- 653 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.
- Trial name
- NCT00698789
- Testing
- INCB019602, Metformin
- Where
- 22 sites in United States
- Volunteers
- 48 people
- Sponsor
- Incyte Corporation
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes
The primary objective of the current study was to investigate the safety and tolerability of BI 1356 BS following administration of multiple rising oral doses of 1 mg, 2.5 mg, 5 mg, and 10 mg over 12 days in male patients with…
- Trial name
- NCT02183350
- Testing
- BI 1356 BS - single rising dose
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)
This is a randomized, double-blind, placebo-controlled Phase Ib/IIa clinical study in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise and/or treated with irregular use of…
- Trial name
- NCT06256523
- Testing
- GZR18
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 2 Diabetes Mellitus
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
The purpose of this study is to demonstrate the efficacy and safety of vildagliptin 50mg qd as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with prior sulfonylurea monotherapy as…
- Trial name
- NCT01357252
- Testing
- vildagliptin
- Where
- 18 sites in China
- Volunteers
- 279 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 1
Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with diabetes mellitus in routine clinical practice in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02230618
- Testing
- insulin degludec/insulin aspart
- Where
- 35 sites in India
- Volunteers
- 1,029 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
SY-009 is a novel compound that inhibits sodium glucose cotransporter-1 (SGLT-1). The preclinical and phase 1 clinical trial data support to carry out phase II clinical trial in diabetes subjects.
- Trial name
- NCT05426018
- Testing
- SY-009 capsules
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Diabetes Mellitus, Type 2
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTO 3649 following a single dose in healthy adults and following multiple doses in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00882726
- Testing
- CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients)
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Type 2 Diabetes Mellitus
Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes
The objective of this study is to evaluate the efficacy and safety of DS-8500a compared with placebo in Japanese patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT02222350
- Testing
- 10mg DS-8500a tablet, 75mg DS-8500a tablet
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes Mellitus
A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of nasal glucagon compared to intramuscular (IM) glucagon for treatment of insulin-induced hypoglycemia in Japanese participants with diabetes mellitus.
- Trial name
- NCT03421379
- Testing
- Glucagon Nasal Powder, Glucagon Hydrochloride Solution
- Where
- 4 sites in Japan
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes
This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes
- Trial name
- NCT00383578
- Testing
- Vildagliptin 100 mg qd, Metformin 1500 mg daily
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients
The purpose is to evaluate the proportion of subjects achieving a Hemoglobin A1c (HbA1c) level below 6.5%, when lispro mix 50/50 is introduced in a stepwise manner from every day (QD) administration to type 2 diabetic patients…
- Trial name
- SIMPLE (NCT00971997)
- Testing
- Lispro Mix 50/50
- Where
- 14 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy
- Trial name
- NCT07816198
- Testing
- AD-233A, AD-233B, AD-233C
- Volunteers
- 354 people
- Sponsor
- Addpharma Inc.
Type 2 Diabetes Mellitus
A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)
A five-period crossover study to assess and compare the trough dipeptidyl peptidase IV (DPP-4) inhibition at 24-hours following the final morning dose for sitagliptin, saxagliptin and vildagliptin after 5 days of once daily…
- Trial name
- NCT01582308
- Testing
- Sitagliptin 100 mg, Saxagliptin 5 mg, Vildagliptin 50 mg
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study of LY2405319 in Participants With Type 2 Diabetes
The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It was given as a daily injection under the skin to participants with type 2 diabetes mellitus (T2DM) for 28 days.
- Trial name
- NCT01869959
- Testing
- LY2405319
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.